Mineralys Therapeutics (MLYS) Assets Average (2023 - 2026)

Mineralys Therapeutics has reported Assets Average for 4 years, with the latest figure at $657.3 million in Q1 2026.

• Quarterly Assets Average rose 134.41% year-over-year to $657.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $657.3 million (up 134.41% YoY) and the FY2025 annual result came in at $433.9 million, up 89.65% from the prior year.
• Assets Average rose to $657.3 million in Q1 2026 per MLYS's latest filing, from $630.9 million in the prior quarter.
• Over five years, Assets Average peaked at $657.3 million in Q1 2026 and troughed at $210.4 million in Q1 2023.
• A 4-year average of $354.1 million and a median of $298.8 million in 2023 frame the typical range for Assets Average.
• The sharpest annual moves came in 2024 and 2025: Assets Average fell 10.4% in 2024, then surged 166.11% in 2025.
• Over 4 years, Assets Average stood at $264.6 million in 2023, then fell by 10.4% to $237.1 million in 2024, then soared by 166.11% to $630.9 million in 2025, then climbed by 4.19% to $657.3 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $657.3 million, $630.9 million, and $467.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.